Covid vaccines IP waiver is 'in direct response to an emergency': Ramaphosa

South African President Cyril Ramaphosa has dedicated his weekly letter to the nation to the issue of waiving intellectual property rights on Covid-19 vaccines, saying it's necessary at this time

Cyril Ramaphosa
South African President Cyril Ramaphosa
AP Cape Town
1 min read Last Updated : May 11 2021 | 6:58 AM IST

South African President Cyril Ramaphosa has dedicated his weekly letter to the nation to the issue of waiving intellectual property rights on COVID-19 vaccines, saying it's necessary at this time and in direct response to an emergency.

Ramaphosa's message reflects his country's hope that the waiver, first proposed by South Africa and India, may still happen despite opposition from nations like Germany.

Ramaphosa writes that the Biden Administration's support for a waiver has given negotiations at the World Trade Organisation added momentum. He compares the vaccine IP waiver issue to South Africa's eventually successful fight two decades ago to ease IPs on life-saving antiretroviral drugs during the HIV/Aids crisis.

And once again, South Africa is waging a struggle that puts global solidarity to the test, Ramaphosa wrote.

European Union leaders have doubted the immediate benefit of a waiver of IPs on COVID-19 vaccines, saying many less developed countries, particularly in Africa, don't have the capacity to manufacture vaccines even if the waiver is achieved.

Ramaphosa writes that South Africa is one of five countries in Africa with vaccine production capacity and a waiver would enable them to bolster global vaccine manufacturing for COVID-19 and other major diseases.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :Coronavirus Vaccineintellectual property rightsCyril Ramaphosa

First Published: May 11 2021 | 6:45 AM IST

Next Story